Literature DB >> 32966647

Krebs von den Lungen-6 (KL-6) is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers.

Yuan Ji1, Stephen J Bourke2, Mark Spears3, Louise V Wain4,5, Gavin Boyd6, Phillip P Lynch7, Matthew Cunningham1, Kenneth Boyd8, Iona Donnelly1, Nobuoki Kohno9, Charles McSharry1.   

Abstract

BACKGROUND: Identifying early stages of hypersensitivity pneumonitis (HP) is hampered by variable presentation, heterogeneous or undetected causal antigens and lack of gold-standard biomarkers. Krebs von den Lungen (KL)-6 is pathophysiological biomarker of alveolar epithelial damage. Pigeon fanciers, susceptible to HP, provide a model to investigate early HP.
OBJECTIVE: To test the hypothesis that plasma concentrations of KL-6 are increased in early-stage acute HP.
METHODS: Clinical history, spirometry and blood samples were obtained from pigeon fanciers, 20 with intermittent acute symptoms indicative of developing HP, 27 with no symptoms and 10 healthy subjects with no avian exposure. Plasma KL-6 (units/mL) and pigeon antigen-specific IgG antibody were quantified by enzyme immunoassay. Blood lymphocytes were quantified by flow cytometry and antigen specificity by in vitro cytokine production.
RESULTS: KL-6 was higher in fanciers than controls, median (IQR) 452 (244, 632) vs 274 (151, 377), P = .01. Although fanciers with symptoms had similar antigen exposure and lung function, they had higher KL-6 than those without, 632 (468, 1314) vs 320 (200, 480), P < .001. KL-6 correlated with IgG antibody titre in those with symptoms, r = .591, P = .006. High KL-6, irrespective of symptom category, was associated with higher antibody (P = .006) and lymphocyte proliferation (P = .041), and lower CD4+ T lymphocyte proportion (P = .032). CONCLUSION AND CLINICAL RELEVANCE: Raised KL-6 is associated with acute symptoms of early-stage HP, and its correlation with antibody may support therapeutic strategies when HP is suspected. KL-6 may act as a mechanistic biomarker of early pathogenesis by linking lung pathophysiological changes with an endotype of immune hypersensitivity.
© 2020 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ILD; KL-6; biomarkers; hypersensitivity pneumonitis

Year:  2020        PMID: 32966647     DOI: 10.1111/cea.13744

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  2 in total

1.  Clinical Utility of Circulating Pneumoproteins as Diagnostic and Prognostic Biomarkers in COVID-19: A Systematic Review and Meta-analysis.

Authors:  Yani Ke; Yuqing Zhu; Shuaihang Chen; Jie Hu; Ruilin Chen; Wu Li; Shan Liu
Journal:  Infect Dis Ther       Date:  2022-08-25

Review 2.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.